|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||81.28 - 83.30|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||11.28|
|Dividend & Yield||3.30 (3.50%)|
|1y Target Est||N/A|
Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.
A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.